Immunotherapy has revolutionized the treatment landscape for cancer, offering hope for patients who have exhausted traditional therapeutic options. In the ever-evolving field of immunotherapy, two emerging approaches—CAR-T cells and CAR-Exosome agents—are garnering attention for their potential to revolutionize the treatment of cancer.
Both harness the power of the body’s immune system to target and destroy cancer cells, but they differ in their mechanisms of action, manufacturing processes, and risk profiles. Understanding the distinction between CAR-T cells and CAR-exosome agents is crucial for evaluating their potential to reshape cancer treatment.
What...
